Literature DB >> 32165136

Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention.

Andrea Carlo Rossetti1, Maria Serena Paladini2, Marco Andrea Riva3, Raffaella Molteni4.   

Abstract

While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, preclinical and clinical evidence suggests that an imbalance in the pro/anti-oxidative homeostasis toward the increased production of substances with oxidizing potential may contribute to the etiology and manifestation of different psychiatric disorders. The substantial and continous demand for energy renders the brain highly susceptible to disturbances in its energy supply, especially following exposure to stressful events, which may lead to overproduction of reactive oxygen and nitrogen species under conditions of perturbed antioxidant defenses. This will eventually induce different molecular alterations, including extensive protein and lipid peroxidation, increased blood-brain barrier permeability and neuroinflammation, which may contribute to the changes in brain function and morphology observed in mental illnesses. This view may also reconcile different key concepts for psychiatric disorders, such as the neurodevelopmental origin of these diseases, as well as the vulnerability of selective cellular populations that are critical for specific functional abnormalities. The possibility to pharmacologically modulate the redox system is receiving increasing interest as a novel therapeutic strategy to counteract the detrimental effects of the unbalance in brain oxidative mechanisms. This review will describe the main mechanisms and mediators of the redox system and will examine the alterations of oxidative stress found in animal models of psychiatric disorders as well as in patients suffering from mental illnesses, such as schizophrenia and major depressive disorder. In addition, it will discuss studies that examined the effects of psychotropic drugs, including antipsychotics and antidepressants, on the oxidative balance as well as studies that investigated the effectiveness of a direct modulation of oxidative mechanisms in counteracting the behavioral and functional alterations associated with psychiatric disorders, which supports the promising role of the redox system as a novel therapeutic target for the improved treatment of brain disorders.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; Antidepressants; Antipsychotics; Major depressive disorder; Redox balance; Schizophrenia

Mesh:

Substances:

Year:  2020        PMID: 32165136     DOI: 10.1016/j.pharmthera.2020.107520

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  9 in total

1.  Paeoniflorin Rescued MK-801-Induced Schizophrenia-Like Behaviors in Mice via Oxidative Stress Pathway.

Authors:  Jia-Quan Liang; Xi Chen; Yong Cheng
Journal:  Front Nutr       Date:  2022-04-27

Review 2.  Depression and Cardiovascular Disease: The Viewpoint of Platelets.

Authors:  Patrizia Amadio; Marta Zarà; Leonardo Sandrini; Alessandro Ieraci; Silvia Stella Barbieri
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

Review 3.  Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Authors:  Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

4.  Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway.

Authors:  Ruozhi Dang; Mingyang Wang; Xinhui Li; Haiyang Wang; Lanxiang Liu; Qingyuan Wu; Jianting Zhao; Ping Ji; Lianmei Zhong; Julio Licinio; Peng Xie
Journal:  J Neuroinflammation       Date:  2022-02-07       Impact factor: 8.322

5.  Neuroprotective Effects of Omentin-1 Against Cerebral Hypoxia/Reoxygenation Injury via Activating GAS6/Axl Signaling Pathway in Neuroblastoma Cells.

Authors:  Xiaochen Niu; Ye Cheng; Meng Zhang; Luyang Du; Xue Wu; Chenxi Lu; Xiyang Li; Shuai Liu; Aizhen Zhao; Shaofei Zhang; Zhen Wu; Baoping Ding; Wenzhen Shi; Changyu Wang; Yang Yang; Ye Tian
Journal:  Front Cell Dev Biol       Date:  2022-01-24

6.  Possible involvement of L-arginine-nitric oxide pathway in the antidepressant activity of Auraptene in mice.

Authors:  Hossein Amini-Khoei; Shakiba Nasiri Boroujeni; Forough Maghsoudi; Mohammad Rahimi-Madiseh; Elham Bijad; Mohammadtaghi Moradi; Zahra Lorigooini
Journal:  Behav Brain Funct       Date:  2022-02-14       Impact factor: 3.759

7.  Oxidative Stress and Psychiatric Disorders: Evidence from the Bidirectional Mendelian Randomization Study.

Authors:  Zhe Lu; Chengcheng Pu; Yuyanan Zhang; Yaoyao Sun; Yundan Liao; Zhewei Kang; Xiaoyang Feng; Weihua Yue
Journal:  Antioxidants (Basel)       Date:  2022-07-18

8.  Altered responsiveness of the antioxidant system in chronically stressed animals: modulation by chronic lurasidone treatment.

Authors:  Vittoria Spero; Maria Serena Paladini; Paola Brivio; Marco Andrea Riva; Francesca Calabrese; Raffaella Molteni
Journal:  Psychopharmacology (Berl)       Date:  2022-04-23       Impact factor: 4.415

Review 9.  Therapeutic Effect and Mechanisms of Essential Oils in Mood Disorders: Interaction between the Nervous and Respiratory Systems.

Authors:  Timothy K H Fung; Benson W M Lau; Shirley P C Ngai; Hector W H Tsang
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.